Image

Zimmer Biomet Shoulder Arthroplasty PMCF

Zimmer Biomet Shoulder Arthroplasty PMCF

Recruiting
20 years and older
All
Phase N/A

Powered by AI

Overview

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

Description

The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.

The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.

Eligibility

Inclusion Criteria:

  • Patient must be 20 years of age or older.
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
  • Patient is a candidate for shoulder arthroplasty due to one or more of the
    following
    • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
    • Rheumatoid arthritis.
    • Correction of functional deformity.
    • Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
    • Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must be able and willing to sign the IRB/EC approved informed consent.
  • Patient has grossly deficient rotator, (for reverse application)
    • With severe arthropathy and/or
    • Previously failed shoulder joint replacement
  • Patient must have functional deltoid muscle (for reverse application)

Exclusion Criteria:

  • Patient is unwilling or unable to give consent or to comply with the follow-up program.
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient is known to be pregnant or breastfeeding.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
  • Patient has osteomalacia.
  • Patient has a metabolic disorder that may impair bone formation.
  • Patient has deficient rotator cuff.
  • Patient presents with significant injury to the upper brachial plexus.
  • Patient has paralysis of the axillary nerve.
  • Patient has non-functional deltoid or external rotator muscles.

Study details
    Shoulder Fractures
    Shoulder Arthritis
    Shoulder Osteoarthritis
    Shoulder Deformity
    Shoulder Injuries
    Shoulder Pain

NCT04984291

Zimmer Biomet

1 November 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.